Status:
RECRUITING
Senescence and the Early Ageing Phenotype After Chemotherapy for Testicular Cancer: the SEA-CAT Study
Lead Sponsor:
University Medical Center Groningen
Collaborating Sponsors:
Dutch Cancer Society
Conditions:
Testicular Cancer
Eligibility:
MALE
18-50 years
Phase:
NA
Brief Summary
Cisplatin-combination chemotherapy causes inevitably DNA damage by platinum-DNA adduct formation of both tumor cells but also healthy cells. It therefore stands to reason that testicular cancer treatm...
Eligibility Criteria
Inclusion
- In order to be eligible to participate in the cross-sectional part of this study, a subject must meet all of the following criteria:
- Diagnosed with metastatic testicular cancer in 1999-2012 (stage II or higher)
- Received first-line cisplatin-based chemotherapy
- Was younger than 50 years of age at start of chemotherapy
- In order to be eligible to participate in the longitudinal part of this study, a subject must meet all of the following criteria:
- Chemotherapy-group:
- Diagnosis of metastatic testicular cancer (stage II or higher)
- Is about to start with first-line cisplatin-based chemotherapy
- Younger than 50 years of age at diagnosis of metastatic testicular cancer
- Stage I control-group:
- Diagnosis of testicular cancer stage I disease
- Younger than 50 years of age at diagnosis of testicular cancer
Exclusion
- A potential subject who meets any of the following criteria will be excluded from participation in this study:
- \- Not able to provide informed consent (in example in case of mental or psychiatric disability)
Key Trial Info
Start Date :
February 9 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2026
Estimated Enrollment :
192 Patients enrolled
Trial Details
Trial ID
NCT04113122
Start Date
February 9 2019
End Date
September 1 2026
Last Update
December 13 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Medical Center Groningen
Groningen, Netherlands, 9713 GZ